Science & Enterprise subscription

Follow us on Twitter

  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 16 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 16 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 20 hours ago
  • New post on Science and Enterprise: Vaccine Stops Lyme Bacteria in Preclinical Test https://t.co/7H0Lc90nRe #Science #Business
    about 20 hours ago
  • Stop the panic porn ... Coronavirus Variants Don’t Have to Be Scary. Still, Mask Up. https://t.co/d6aDu2Ucj6
    about 23 hours ago

Please share Science & Enterprise

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

2020 Venture Funds Mixed, Biotech Keeps Sizzling

2020 venture transactions

Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling

Covid-19 Antibody Developer Raises $483M in IPO

Wall Street sign

A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO

Venture Rounds, IPOs, Mergers Vanish in Election Week

White House

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week

Covid-19 Drug Biotech Raises $300M in IPO

Wall Street sign

A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock. . . . → Read More: Covid-19 Drug Biotech Raises $300M in IPO

Mental Health Drug Company Raises $127.5M in IPO

NASDAQ share price display

A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO

Cancer Protein Therapy Biotech Raises $400M in IPO

Wall Street sign

A three year-old company developing protein-targeted cancer therapies with computational techniques is raising $400 million in its initial public offering of common stock. . . . → Read More: Cancer Protein Therapy Biotech Raises $400M in IPO

Migraine Drug Developer Raises $82.5M in IPO

NASDAQ share price display

A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO

Two Biotechs Each Issue $300M+ IPOs

NASDAQ share price display

Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs

Genome Editing Biotech Raises $126M in IPO

NASDAQ share price display

A biotechnology company developing treatments for disease and enhanced agricultural products with genome editing is raising $126 million in its initial public offering, or IPO, of common stock. . . . → Read More: Genome Editing Biotech Raises $126M in IPO